The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for commercialisation.

Charlotte, N.C.-based SonaCare Medical earned clearance from the Food and Drug Administration for a new version of its Sonablate device. Sonablate, intended for use in the focused ablation of prostate ...

The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued draft guidance Tuesday to support clinical testing of high-intensity ultrasound systems for ...

ProUroCare Medical, Inc., of Minneapolis, Minn., has filed a de novo application with the FDA seeking marketing clearance for its prostate mechanical imaging (PMI) device (ProUroScan). This will allow ...

Industry trade associations made the case for revisions to draft guidance on clinical testing recommendations for prostate tissue ablation devices in comments earlier this month. The Medical Imaging & ...

Transrectal ultrasound guided (TRUS) biopsy has been the gold standard for prostate cancer diagnosis, but carries a significant risk of urinary tract infection, sometimes requiring hospital admission ...

WEST LAFAYETTE, Ind. - A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease. A team of Purdue University researchers has synthesized ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

(WDBJ) - September is National Prostate Cancer Awareness month. One in eight men will develop prostate cancer in their lifetimes, and 35,000 men will die this year from it. For many men, it’s a ...